Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.05
ACT's Cash to Debt is ranked lower than
94% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.47 vs. ACT: 0.05 )
Ranked among companies with meaningful Cash to Debt only.
ACT' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.54 Max: 43.62
Current: 0.05
0.02
43.62
Equity to Asset 0.54
ACT's Equity to Asset is ranked lower than
62% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. ACT: 0.54 )
Ranked among companies with meaningful Equity to Asset only.
ACT' s Equity to Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.62 Max: 0.93
Current: 0.54
0.25
0.93
F-Score: 6
Z-Score: 1.21
M-Score: -2.45
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) -13.55
ACT's Operating margin (%) is ranked lower than
82% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.51 vs. ACT: -13.55 )
Ranked among companies with meaningful Operating margin (%) only.
ACT' s Operating margin (%) Range Over the Past 10 Years
Min: -21.33  Med: 9.40 Max: 14.13
Current: -13.55
-21.33
14.13
Net-margin (%) 21.03
ACT's Net-margin (%) is ranked higher than
87% of the 684 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.44 vs. ACT: 21.03 )
Ranked among companies with meaningful Net-margin (%) only.
ACT' s Net-margin (%) Range Over the Past 10 Years
Min: -22.48  Med: 5.41 Max: 9.4
Current: 21.03
-22.48
9.4
ROE (%) 6.56
ACT's ROE (%) is ranked lower than
52% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.23 vs. ACT: 6.56 )
Ranked among companies with meaningful ROE (%) only.
ACT' s ROE (%) Range Over the Past 10 Years
Min: -23.54  Med: 6.12 Max: 12.05
Current: 6.56
-23.54
12.05
ROA (%) 3.62
ACT's ROA (%) is ranked higher than
50% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. ACT: 3.62 )
Ranked among companies with meaningful ROA (%) only.
ACT' s ROA (%) Range Over the Past 10 Years
Min: -13.02  Med: 3.52 Max: 6.67
Current: 3.62
-13.02
6.67
ROC (Joel Greenblatt) (%) -47.27
ACT's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.81 vs. ACT: -47.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ACT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -37.89  Med: 22.90 Max: 39.38
Current: -47.27
-37.89
39.38
Revenue Growth (3Y)(%) 17.90
ACT's Revenue Growth (3Y)(%) is ranked higher than
79% of the 581 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. ACT: 17.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ACT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 6.4  Med: 17.55 Max: 40.5
Current: 17.9
6.4
40.5
EBITDA Growth (3Y)(%) -3.70
ACT's EBITDA Growth (3Y)(%) is ranked lower than
65% of the 528 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. ACT: -3.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ACT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -4.4  Med: 5.60 Max: 33.2
Current: -3.7
-4.4
33.2
» ACT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ACT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Allergan PLC

SymbolPriceYieldDescription
AGNPRA923.054.455 1/2 % Cum.Conv.Pref.Shs 2015-1.3.18 Series -A-

Guru Investment Theses on Allergan PLC

Vanguard Health Care Fund Comments on Actavis PLC - Mar 27, 2015

Actavis (ACT) is a specialty pharmaceutical company that develops generic and branded products. We owned Actavis prior to its Forest Labs acquisition but increased our position. We are attracted to the uniqueness of the combined company’s business model, which provides exposure to both generic and branded pharmaceuticals globally. The company’s Irish tax rate could also be strategically important in future mergers and acquisitions. Actavis was the fund’s second-largest holding as of the end of the period.



From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report.



Check out Vanguard Health Care Fund latest stock trades

Bernard Horn Comments on Actavis PLC - Oct 30, 2014

On July 1, Actavis (ACT) announced the completion of its acquisition of Forest Laboratories Inc. (a Fund holding), in a cash and equity transaction valued at approximately $28 billion. We maintained a position in Actavis, as its pro-forma financial statements fit the Polaris valuation profile. As one of the largest generic pharmaceutical companies, Actavis is expected to broaden its product platform with the Forest acquisition, increase operating cash flow and realize $1 billion in cost synergies.

From Bernard Horn (Trades, Portfolio)’s Polaris Global Value Fund Q3 2014 Shareholder Letter.

Check out Bernard Horn latest stock trades

Diamond Hill Capital Comments on Actavis PLC - Jul 25, 2014

We eliminated our position in specialty pharmaceutical company Actavis PLC (ACT) as the price to intrinsic value relationship narrowed. We originally received shares when Actavis bought portfolio holding Warner Chilcott.

From Diamond Hill Capital (Trades, Portfolio)'s Small Cap Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Actavis Inc - Jun 26, 2014

Pharmaceutical company Actavis, Inc. PLC (ACT) announced the acquisition of drug manufacturer Forest Laboratories, Inc. during the quarter for a combination of cash and stock. Investors viewed this as a positive for Actavis due to expected synergies and an increase in the branded drug business as a percent of revenues.



From Diamond Hill Capital's Small Cap Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Allergan PLC

John Paulson's First-Quarter Moves Alter Largest And Most Valuable Stakes
Hedge fund manager John Paulson (Trades, Portfolio), founder and president of Paulson & Co. Inc., the third-largest hedge fund in the world, has been called “one of the most prominent names in high finance” by The New York Times. He rocketed to prominence by making $3.7 billion in 2007 using credit default swaps in a gamble against the U.S. subprime mortgage lending market. Read more...
John Paulson Buys Actavis, AIG, Valeant, Sells Equinix, Alibaba
Hedge fund giant John Paulson (Trades, Portfolio) just reported his first quarter portfolio. He buys Actavis PLC, AIG, Valeant, Computer Sciences, etc during the 3-months ended 2015-03-31, according to the most recent filings of his investment company, Paulson & Co.. As of 2015-03-31, Paulson & Co. owns 57 stocks with a total value of $19 billion. These are the details of the buys and sells.
Read more...
Vanguard Health Care Fund Comments on Actavis PLC
Actavis (ACT) is a specialty pharmaceutical company that develops generic and branded products. We owned Actavis prior to its Forest Labs acquisition but increased our position. We are attracted to the uniqueness of the combined company’s business model, which provides exposure to both generic and branded pharmaceuticals globally. The company’s Irish tax rate could also be strategically important in future mergers and acquisitions. Actavis was the fund’s second-largest holding as of the end of the period. Read more...
Bernard Horn's Most Heavily Weighted Stocks
Bernard Horn (Trades, Portfolio) of Polaris Global Value Fund currently owns 89 stocks, valued at $275 million, with a quarter over quarter turnover of 4%. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 36.10
ACT's P/E(ttm) is ranked lower than
64% of the 804 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.47 vs. ACT: 36.10 )
Ranked among companies with meaningful P/E(ttm) only.
ACT' s P/E(ttm) Range Over the Past 10 Years
Min: 11.01  Med: 26.99 Max: 485.71
Current: 36.1
11.01
485.71
Forward P/E 14.66
ACT's Forward P/E is ranked higher than
60% of the 413 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.38 vs. ACT: 14.66 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.54
ACT's P/B is ranked higher than
76% of the 927 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.50 vs. ACT: 1.54 )
Ranked among companies with meaningful P/B only.
ACT' s P/B Range Over the Past 10 Years
Min: 1.03  Med: 1.77 Max: 5.9
Current: 1.54
1.03
5.9
P/S 5.18
ACT's P/S is ranked lower than
83% of the 927 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. ACT: 5.18 )
Ranked among companies with meaningful P/S only.
ACT' s P/S Range Over the Past 10 Years
Min: 0.99  Med: 1.84 Max: 5.82
Current: 5.18
0.99
5.82
PFCF 30.07
ACT's PFCF is ranked higher than
55% of the 492 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.39 vs. ACT: 30.07 )
Ranked among companies with meaningful PFCF only.
ACT' s PFCF Range Over the Past 10 Years
Min: 6.64  Med: 14.17 Max: 39.29
Current: 30.07
6.64
39.29
POCF 25.62
ACT's POCF is ranked lower than
53% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.33 vs. ACT: 25.62 )
Ranked among companies with meaningful POCF only.
ACT' s POCF Range Over the Past 10 Years
Min: 5.97  Med: 11.78 Max: 33.27
Current: 25.62
5.97
33.27
EV-to-EBITDA 60.29
ACT's EV-to-EBITDA is ranked lower than
90% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.32 vs. ACT: 60.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -224.1  Med: 9.70 Max: 105.7
Current: 60.29
-224.1
105.7
Shiller P/E 601.43
ACT's Shiller P/E is ranked lower than
96% of the 169 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.70 vs. ACT: 601.43 )
Ranked among companies with meaningful Shiller P/E only.
ACT' s Shiller P/E Range Over the Past 10 Years
Min: 14.67  Med: 47.01 Max: 817.85
Current: 601.43
14.67
817.85
Current Ratio 2.05
ACT's Current Ratio is ranked lower than
54% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. ACT: 2.05 )
Ranked among companies with meaningful Current Ratio only.
ACT' s Current Ratio Range Over the Past 10 Years
Min: 1.31  Med: 2.93 Max: 9.8
Current: 2.05
1.31
9.8
Quick Ratio 1.89
ACT's Quick Ratio is ranked higher than
56% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. ACT: 1.89 )
Ranked among companies with meaningful Quick Ratio only.
ACT' s Quick Ratio Range Over the Past 10 Years
Min: 0.78  Med: 2.00 Max: 8.82
Current: 1.89
0.78
8.82
Days Inventory 125.57
ACT's Days Inventory is ranked lower than
54% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.42 vs. ACT: 125.57 )
Ranked among companies with meaningful Days Inventory only.
ACT' s Days Inventory Range Over the Past 10 Years
Min: 108.18  Med: 121.54 Max: 133.19
Current: 125.57
108.18
133.19
Days Sales Outstanding 43.14
ACT's Days Sales Outstanding is ranked higher than
79% of the 584 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.67 vs. ACT: 43.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.05  Med: 66.96 Max: 92.81
Current: 43.14
39.05
92.81
Days Payable 29.86
ACT's Days Payable is ranked lower than
87% of the 563 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.59 vs. ACT: 29.86 )
Ranked among companies with meaningful Days Payable only.
ACT' s Days Payable Range Over the Past 10 Years
Min: 26.19  Med: 59.63 Max: 107.57
Current: 29.86
26.19
107.57

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.41
ACT's Price/Projected FCF is ranked higher than
78% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. ACT: 1.41 )
Ranked among companies with meaningful Price/Projected FCF only.
ACT' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.59  Med: 1.14 Max: 3.29
Current: 1.41
0.59
3.29
Price/Median PS Value 2.13
ACT's Price/Median PS Value is ranked lower than
85% of the 913 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. ACT: 2.13 )
Ranked among companies with meaningful Price/Median PS Value only.
ACT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.67  Med: 1.35 Max: 5.39
Current: 2.13
0.67
5.39
Earnings Yield (Greenblatt) (%) -1.80
ACT's Earnings Yield (Greenblatt) (%) is ranked lower than
75% of the 720 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. ACT: -1.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ACT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1  Med: 6.30 Max: 12.3
Current: -1.8
1
12.3
Forward Rate of Return (Yacktman) (%) 8.19
ACT's Forward Rate of Return (Yacktman) (%) is ranked higher than
54% of the 318 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.62 vs. ACT: 8.19 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ACT' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -1.9  Med: 8.40 Max: 17.8
Current: 8.19
-1.9
17.8

More Statistics

Revenue(Mil) $13062
EPS $ -7.42
Short Percentage of Float1.14%
52-Week Range $201.91 - 317.72
Shares Outstanding(Mil)392.44

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:A60.Germany, AGN N.Mexico,
Allergan PLC, formerly known as Actavis PLC was incorporated in Ireland on May 16, 2013. It is an integrated specialty pharmaceutical company. The Company is engaged in development, manufacturing, marketing, sale and distribution of generic, branded generic, brand name, biosimilar and over-the-counter pharmaceutical products. It also develops and out-license generic pharmaceutical products in Europe through its Medis third-party business. It operates in three segments, Pharma, Specialty Brands and Anda Distribution. The Pharma segment includes off-patent pharmaceutical products that are therapeutically equivalent to proprietary products. The Specialty Brands segment includes patent-protected products and certain trademarked off-patent products that the Company sells and markets as brand pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products manufactured by third parties, as well as by the Company to independent pharmacies, pharmacy chains, pharmacy buying groups and physicians' offices. It competes with generic manufacturers of pharmaceutical products. It is subject to extensive, complex and evolving regulation by the federal government, the FDA, and to a lesser extent, by the U.S. Drug Enforcement Administration Occupational Safety and Health Administration and state government agencies, as well as by various regulatory agencies in foreign countries where its products or product candidates are being manufactured and/or marketed. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other federal statutes and regulations govern or influence the testing, manufacturing, packing, labeling, storing, record keeping, safety, approval, advertising, promotion, sale and distribution of its products.
» More Articles for ACT

Headlines

Articles On GuruFocus.com
Vanguard Health Care Fund Sells Stake in Humana Feb 03 2016 
Bill Ackman’s Fund Falls by Double Digits Again in January Feb 02 2016 
Baron Funds Comments on Allergan Jan 27 2016 
Bill Ackman's Pershing Square Annual Investor Letter Jan 27 2016 
Dalio, Tepper, Klarman Ranked Best Hedge Fund Managers Jan 26 2016 
Weitz Funds Comments on Allergan Jan 25 2016 
Wallace Weitz Comments on Allergan Jan 22 2016 
2 Stocks Super Investors Are Buying in Large Quantities Dec 26 2015 
5 Top Stocks of the Outperforming Vanguard Health Care Fund Dec 28 2015 
5 Guru Picks in Volatile Biotech Industry Dec 23 2015 

More From Other Websites
How Will Teva Finance the Actavis Acquisition? Jan 21 2016
How the Teva-Actavis Deal Benefits Teva Dec 07 2015
Allergan drops appeal of order blocking Alzheimer's drug switch Nov 25 2015
ALLERGAN PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or... Nov 24 2015
10 Stocks George Soros Is Buying in 2015 Nov 20 2015
Shareholders Should Love Allergan Insider Trading Nov 12 2015
CPHR: Total Revenue Grew 28% in Third Quarter of 2015 Nov 05 2015
Allergan Beats Q3 Estimates Amid M&A, Pricing Talk Nov 04 2015
Orexo Settles Abstral® US Patent Litigation with Actavis Oct 27 2015
IBB’s American Depository Receipts Underperformed Last Week Oct 08 2015
CPHR: Cipher Settles Patent Litigation for Absorica® Oct 07 2015
Why Did These 4 S&P 500 Companies Hire Outsiders as Their Chief Executives? Sep 18 2015
This Is What Hedge Funds Have To Say About Pharmaceutical Giant Allergan plc (AGN) Sep 12 2015
Endo Wins Order Blocking Generic of Opana ER Until 2023 Aug 14 2015
VRX drove Pershing Square Capital Management in July. PAH did not Aug 07 2015
Allergan reports 2Q loss due to recent deals Aug 06 2015
ALLERGAN PLC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Aug 06 2015
Actavis reports 2Q loss Aug 06 2015
Actavis reports 2Q loss Aug 06 2015
Allergan Reports Exceptional Second Quarter 2015 Performance with 116% Increase in Net Revenue to... Aug 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK